Genmab ADR (NASDAQ: GMAB) on Tuesday, plunged -0.13% from the previous trading day, before settling in for the closing price of $22.78. Within the past 52 weeks, GMAB’s price has moved between $22.22 and $32.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 43.21%. The company achieved an average annual earnings per share of 30.93%. With a float of $635.05 million, this company’s outstanding shares have now reached $653.30 million.
The extent of productivity of a business whose workforce counts for 2204 workers is very important to gauge. In terms of profitability, gross margin is 96.83%, operating margin of 31.65%, and the pretax margin is 39.39%.
Genmab ADR (GMAB) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Genmab ADR is 0.00%, while institutional ownership is 7.73%.
Genmab ADR (GMAB) Latest Financial update
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported 0.47 earnings per share (EPS) for the period falling under the consensus outlook (set at 3.14) by -2.67. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.93% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.10% during the next five years compared to 20.52% growth over the previous five years of trading.
Genmab ADR (NASDAQ: GMAB) Trading Performance Indicators
Genmab ADR (GMAB) is currently performing well based on its current performance indicators. A quick ratio of 5.02 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.25. Likewise, its price to free cash flow for the trailing twelve months is 15.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.22, a number that is poised to hit 0.31 in the next quarter and is forecasted to reach 1.39 in one year’s time.
Technical Analysis of Genmab ADR (GMAB)
The latest stats from [Genmab ADR, GMAB] show that its last 5-days average volume of 1.2 million was superior to 0.66 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 44.74%. Additionally, its Average True Range was 0.41.
During the past 100 days, Genmab ADR’s (GMAB) raw stochastic average was set at 8.93%, which indicates a significant decrease from 50.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 16.03% in the past 14 days, which was lower than the 24.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.68, while its 200-day Moving Average is $27.29. Now, the first resistance to watch is $23.00. This is followed by the second major resistance level at $23.25. The third major resistance level sits at $23.66. If the price goes on to break the first support level at $22.34, it is likely to go to the next support level at $21.93. The third support level lies at $21.68 if the price breaches the second support level.
Genmab ADR (NASDAQ: GMAB) Key Stats
Market capitalization of the company is 14.45 billion based on 661,768K outstanding shares. Right now, sales total 2,392 M and income totals 631,910 K. The company made 779,510 K in profit during its latest quarter, and 203,170 K in sales during its previous quarter.
